Kolester

Atorvastatin, the active ingredient in Kolester, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels in adults with hypercholesterolemia or mixed dyslipidemia, helping to reduce the risk of cardiovascular events.

GNH USA supplies Kolester as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Its global logistics network ensures timely delivery and product integrity across diverse markets.

Atorvastatin is used to manage lipid disorders by lowering LDL‑cholesterol and triglycerides.

Hypercholesterolemia: reduces LDL‑cholesterol to lower cardiovascular risk. Mixed dyslipidemia: improves the overall lipid profile including triglycerides and HDL‑cholesterol. Primary and secondary prevention of cardiovascular disease: decreases incidence of heart attack, stroke and related events in at‑risk patients.

Atorvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Muscle aches or weakness - Elevated liver enzymes (ALT, AST) - Headache - Nausea or abdominal discomfort - Diarrhea - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis (severe muscle breakdown) - Acute liver injury or hepatitis - Severe allergic reactions (rash, angioedema, anaphylaxis) - Myopathy with marked CK elevation - Interstitial lung disease (rare) - Thrombocytopenia (rare)

When prescribing atorvastatin, clinicians should observe several safety measures.

- Monitor liver function: obtain baseline ALT/AST and repeat periodically during therapy. - Assess muscle symptoms: discontinue if severe myalgia, tenderness or unexplained CK rise occurs. - Avoid strong CYP3A4 inhibitors: concomitant use can markedly increase atorvastatin exposure. - Use caution in renal impairment: dose adjustment may be required in severe kidney disease. - Counsel patients on pregnancy and lactation: statins are generally contraindicated; discuss risks. - Store at room temperature: keep tablets in original container, protect from moisture and heat.

Atorvastatin interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir): raise atorvastatin levels and risk of myopathy. - Gemfibrozil: synergistic effect on muscle toxicity. - Cyclosporine: increases statin exposure and muscle injury risk. - Protease inhibitors (e.g., lopinavir/ritonavir): potentiate statin concentrations. - Colchicine: heightened risk of severe myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: atorvastatin may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: possible increase in serum digoxin concentrations. - Antacids (e.g., aluminum hydroxide): may modestly affect atorvastatin absorption.